Development and Characterization of Pioglitazone Nanoparticles for the Effective Treatment of Diabetes Mellitus

Abstract

Pioglitazone is designated as a BCS class II medication since it is weakly water soluble.The goal of this study was to create starch nanoparticles for the administration of Pioglitazone in attempt to lessen dose-related side effects and maybe prolong its release in the treatment of diabetes.Using starch as a polymer, tween 80 as a stearic barrier, and citric acid to enhance stability, nanoparticles were constructed using the solvent evaporation technique. In-vitro characterization techniques for drug-polymer compatibility, size, surface morphology, encapsulation efficacy, and delivery properties were performed on framed nanoparticles, followed by In-vivo studies.The compatible nature of selected excipients for the manufacture of Pioglitazone nanoparticles was shown by FTIR findings.The results of the XRD analysis revealed that the generated Pioglitazone nanoparticles were non-crystalline in nature.The selected developed Pioglitazone nanoparticles were in cubic phase with average particle size of 160.5 ± 11.24–245.4 ± 15.96 nm with charge ranging from 10.5 ± 6.21-138.6 ± 5.31mV.The encapsulation efficiency of Pioglitazone nanoparticles produced ranged from 57.24 5.80 to 89.96 1.9%. The In-vitro drug release studies of Pioglitazone nanoparticles showed controlled drug release profile. Furthermore, In-vivo investigations on blood glucose profiles revealed that the created Pioglitazone nanoparticles for the treatment of diabetes mellitus had a substantial effect. Original Research Article Gupta and Odayakumar; JPRI, 33(31A): 172-182, 2021; Article no.JPRI.69332 173